Clinical trials: Human Cancers
Cancer
68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy
In this project, based on the DTPA-HAS kit, investigators plan to develop a positron nuclide 68Ga labeled DTPA-HSA molecular probe in order to obtain high sensitivity, signal-to-noise ratio and high-resolution PET/CT imaging…
- Trial name
- PLE-PET (NCT06716788)
- Testing
- 68Ga-HSA
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Cancer Hospital & Institute
Anal Canal Cancer
Screening for Anal Cancer and Precancer in Women With HIV (SANCA)
The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic…
- Trial name
- SANCA (NCT07059442)
- Testing
- anal HPV screening
- Where
- Sweden
- Volunteers
- 1,000 people
- Sponsor
- Karolinska Institutet
Sezary Syndrome, Ichthyosis, Lamellar
Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
Autosomal recessive congenital ichthyoses (ARCI) are monogenic diseases of cornification that correspond to a diffuse abnormality (affecting the entire integument) of epidermal differentiation and therefore of the skin barrier.
- Trial name
- NIPALYMPHO (NCT07477769)
- Testing
- blood sampling
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Soft Tissue Sarcoma
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.
- Trial name
- FLASH (NCT04733183)
- Testing
- Dacarbazine, onfekafusp alfa
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 98 people
- Sponsor
- Philogen S.p.A.
Glioma, Patient Reported Outcome Measures
Validity and Reliability Evaluation of the PRO-CTCAE for Adult-type Diffuse Gliomas Patients in Chinese Population
Given the increasing importance of patient's perspective in adverse events reporting, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) has been proposed as new PRO measures in…
- Conditions
- Glioma, Patient Reported Outcome Measures, Self Report, Adverse Effects
- Trial name
- VERONICA (NCT05486923)
- Where
- 14 sites in China
- Volunteers
- 450 people
- Sponsor
- Huashan Hospital
Acute Myeloid Leukemia (AML)
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the…
- Trial name
- NCT06760260
- Testing
- Human Derived anti-CI135 CAR-T Injection
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
HIV Infections, HPV Infection
Immunogenicity and Safety of a 9-valent Human Papillomavirus Vaccine in HIV-positive Women
In adult HIV-positive patients, data on the safety and immunogenicity of the quadrivalent HPV (qHPV) vaccine have been reported with excellent results (13 14); also, the results of a clinical trial of qHPV vaccine conducted in…
- Trial name
- 9-VPH-MVIH (NCT04270773)
- Testing
- Human Papillomavirus 9-valent Vaccine, Recombinant
- Where
- Spain
- Volunteers
- 158 people
- Sponsor
- University Hospital Virgen de las Nieves
Prostatic Neoplasms
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the…
- Trial name
- NCT07082920
- Testing
- JNJ-78278343, JNJ-95298177, JNJ-87189401
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Janssen Research & Development, LLC
Advanced Solid Tumors
A Phase I Study of MSB2311 in Advanced Solid Tumors
This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.
- Trial name
- NCT03463473
- Testing
- 3 mg/kg Q3W MSB2311 Injection, 10 mg/kg Q3W MSB2311 Injection, 20 mg/kg Q3W MSB2311 Injection
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT06083207
- Testing
- IBI3003
- Where
- 13 sites in Australia, China
- Volunteers
- 116 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Esophageal Cancer, Advanced Lung Cancer
A First-in-human (FIH), Open-Label, Dose Escalation and Expansion Cohorts Study of MC002
The goal of this clinical trial is to learn if ADC drug MC002 works to treat locally advanced/metastatic solid tumors in adults. It will also learn about the safety of MC002.
- Trial name
- NCT07726212
- Testing
- MC002（ADC）
- Volunteers
- 143 people
- Sponsor
- Hangzhou MacroLink Biopharmaceutical LLC
HPV (Human Papillomavirus)-Associated, HPV Immunization Status
The Effect of HPV Education Provided to Women on Their Knowledge Levels, HPV Screening, and Vaccination Uptake
Type of Study: This study was planned to be an observational study. Purpose of the Study: To evaluate the impact of HPV education given to women on their knowledge levels and HPV screening and vaccination.The main question[s] it…
- Trial name
- HPV-Education (NCT07320157)
- Testing
- Online Education Intervention Group, Contral Group
- Where
- Turkey (Türkiye)
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Ufuk University
Advanced Malignant Solid Tumor
A Study of JSKN027 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase 1 (Ia/Ib) clinical study conducted in China to evaluate the safety and tolerability of JSKN027 in patients with advanced malignant solid tumors.
- Trial name
- NCT07391644
- Testing
- JSKN027
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Multiple Myeloma, Plasma Cell Neoplasm
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
RATIONALE: Antibodies, such as human immune globulin, can block the growth of abnormal cells in different ways. Some block the ability of abnormal cells to grow and spread.
- Trial name
- NCT00547365
- Testing
- Human immune globulin intravenous (IGIV)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Tennessee
Human Papilloma Virus, Cervical Dysplasia
Educational Video's Impact on Knowledge Regarding Cervical Cancer Screening
The researchers will be conducting a prospective randomized trial where the researchers will be introducing an educational video to see whether there is an increase in knowledge scores surrounding cervical cancer, cervical cancer…
- Trial name
- NCT05756192
- Testing
- Educational video
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- George Washington University
Cervical Cancer, Oropharyngeal Cancer
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Background: The human papillomavirus (HPV) can cause a number of cancers, including cervical and throat cancers. The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy that involves taking white…
- Conditions
- Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer
- Trial name
- NCT01585428
- Testing
- Fludarabine, Cyclophosphamide, Young TIL
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus Associated Carcinomas, Cervical Cancer
SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
- Conditions
- Human Papillomavirus Associated Carcinomas, Cervical Cancer, Head and Neck Cancers, Anal Cancer
- Trial name
- NCT06544720
- Testing
- SCG142 TCR-T cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Prostatic Neoplasms
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is…
- Trial name
- NCT07319871
- Testing
- Pasritamig, JNJ-86974680
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 40 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.